ILIAS Biologics signed a collaborative research agreement with JW Pharmaceutical.

The two companies aim to develop an exosome-based small molecular anti-cancer treatment together. We made this agreement with JW only two weeks after announcing our partnership with HK InnoN, another pharma leader in Korea. ILIAS will maximize these open innovation efforts with two pharma leaders to advance exsome-based solutions for intractable diseases.

https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202206140260&t=NN